View ValuationKMPHARMACEUTICALLtd 将来の成長Future 基準チェック /06現在、 KMPHARMACEUTICALLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長30.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).お知らせ • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.お知らせ • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea分析記事 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).お知らせ • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South KoreaNew Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、KMPHARMACEUTICALLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A225430 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202515,990-3,968-2,013-1,751N/A9/30/202515,093-4,678-2,058-1,635N/A6/30/202514,015-4,612-2,588-2,013N/A3/31/202514,088-4,881-1,935-1,544N/A12/31/202414,475-4,573-2,405-2,036N/A9/30/202414,545-3,648-1,253-1,062N/A6/30/202415,295-3,208-346-326N/A3/31/202417,095-1,817660669N/A12/31/202317,770-1,3201,3331,446N/A9/30/202317,580-2,776-271-105N/A6/30/202317,711-3,266-228-53N/A3/31/202316,044-3,905-1,410-1,239N/A12/31/202215,631-3,925-151-93N/A9/30/202218,805-1,8641,4351,440N/A6/30/202220,000-1,271163291N/A3/31/202222,043-670173-2,203N/A12/31/202122,705-611-982,267N/A9/30/202121,335-229-1,4832,049N/A6/30/202121,164-15-5383,411N/A3/31/202122,51873-2,0835,523N/A12/31/202022,928471-2,828909N/A9/30/202022,844-512-12,399-748N/A6/30/202023,443-552-11,414107N/A3/31/202021,326-612-16,537-135N/A12/31/201920,338-902-17,498-701N/A9/30/201919,731233N/A793N/A6/30/201918,406-12,319N/A-1,410N/A3/31/201917,477-12,561N/A413N/A12/31/201817,302-12,330N/A1,217N/A9/30/201816,654-12,004N/A7,867N/A12/31/201716,9151,752N/A336N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A225430の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A225430の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A225430の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A225430の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A225430の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A225430の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:50終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KMPHARMACEUTICAL Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 400% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.0b free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (400% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩72.1b market cap, or US$48.5m).
お知らせ • Mar 26KM Pharmaceutical Co., Ltd. Expands Functional Skincare And Oral Care Product PortfolioKM Pharmaceutical Co. Ltd. is strengthening its global position by expanding into high-value functional product categories across haircare, skincare, and oral care. KM Pharmaceutical is strategically expanding its product portfolio to focus on functional and OTC-driven categories with strong global demand. In haircare, the company is developing products targeting: Hair loss symptom relief (functional scalp care), Scalp inflammation soothing, Scalp barrier strengthening. In skincare, the company is strengthening its functional cosmetic lineup with: Brightening (whitening) solutions, Anti-wrinkle and firming products, Skin barrier repair and strengthening, Anti-inflammatory and soothing formulations for sensitive skin. In oral care, KM Pharmaceutical is expanding its OTC-focused portfolio with: Teeth whitening solutions, Gum disease prevention products, Gingivitis and periodontitis prevention formulations. These categories reflect the company's strategic direction toward high-efficacy, clinically positioned products that align with global consumer demand for functional and results-driven personal care. Skincare continues to be a key growth driver for KM Pharmaceutical's global business.
お知らせ • Mar 17KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
分析記事 • Feb 06Is KMPHARMACEUTICALLtd (KOSDAQ:225430) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Feb 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.6b market cap, or US$12.7m).
New Risk • Jan 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.4b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.1b free cash flow). Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (₩14.4b market cap, or US$9.94m).
New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩16.6b market cap, or US$11.9m).
お知らせ • Mar 18KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025KMPHARMACEUTICAL Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 08:00 Tokyo Standard Time. Location: conference room, 121, pyeongtaekhang-ro 268beon-gil, poseung-eup, gyeonggi-do, pyeongtaek South Korea
New Risk • Mar 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩18.5b market cap, or US$12.8m).
New Risk • Feb 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.5b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩14.5b market cap, or US$9.97m).
Is New 90 Day High Low • Feb 23New 90-day low: ₩2,675The company is down 20% from its price of ₩3,325 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩2,795The company is down 7.0% from its price of ₩3,020 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: ₩2,815The company is down 5.0% from its price of ₩2,965 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,845The company is down 16% from its price of ₩3,380 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: ₩3,125The company is down 3.0% from its price of ₩3,235 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.